


# MAPS: Who We Are



## Executive



Rick Doblin, Ph.D.,  
Founder and  
Executive Director



Merete Christiansen,  
Executive Manager  
and Assistant to  
Rick Doblin, Ph.D.

## Clinical Research



Alia Lilienstein, M.D.,  
M.P.H., Clinical  
Research Associate  
- Physician



Berra Yazar-Klosinski, Ph.D.,  
Associate Director of  
Clinical Research

## Communications and Marketing



Brian Brown,  
Communications and  
Marketing Manager



Brad Burge,  
Director of Strategic  
Communications



Sarah Jordan,  
Publications  
Associate



Cara LaChance,  
Social Media  
Communications and  
Marketing Associate



Amy Mastrine,  
Web and Email  
Marketing Associate



Bryce Montgomery,  
Associate Director  
of Communications  
and Marketing

## Development



Erik Brown,  
Development Manager



Tess Shelley,  
Development  
Specialist



Jade Netanya Ullmann,  
Development Officer  
and Connector



Ryan Beauregard,  
Zendo Project Manger



Sara Gael, M.A.,  
Director of  
Harm Reduction,  
Zendo Project

## Harm Reduction (Zendo Project)

## Operations



Aidan Boling,  
Operations Associate



Kynthia Brunette,  
Information Systems  
Specialist



Jenni Vierra,  
Sales and Outreach  
Associate


## Policy and Advocacy



Ismail L. Ali, JD  
Policy & Advocacy  
Counsel



Natalie Lyla Ginsberg,  
Policy & Advocacy  
Director



# MAPS Public Benefit Corporation

The **MAPS Public Benefit Corporation (MPBC)** is a wholly owned subsidiary of MAPS. The special purpose of MPBC is to balance income from the legal sale of MDMA with the social benefits of MAPS' mission by serving as a vehicle for conducting MAPS' psychedelic and marijuana research initiatives.

MPBC's primary work is completing Phase 2 studies of MDMA-assisted psychotherapy for PTSD, and preparing for the Phase 3 clinical trials required to develop MDMA-assisted psychotherapy into an approved treatment for PTSD. MAPS continues to conduct education and harm reduction projects, to raise funds for MPBC projects, and serve as parent organization and sole funder of MPBC. MPBC was incorporated on December 19, 2014.

## MAPS Public Benefit Corporation



Amy Emerson,  
Executive Director and  
Director of Clinical  
Research



Michael Mithoefer, M.D.,  
MDMA/PTSD Study  
Clinical Investigator/  
Medical Monitor



Annie Mithoefer, B.S.N.,  
MDMA/PTSD Study  
Co-Investigator



Shannon Clare Carlin,  
M.A., MFTI, MDMA  
Therapy Training  
Program Manager



Allison Feduccia, Ph.D.,  
Clinical Data Scientist



Gabby Fortier,  
Clinical Research  
Associate



Connor Harada,  
Clinical Study Assistant



Charlotte Harrison,  
Senior Clinical  
Research Associate



Colin Hennigan,  
Clinical Data Manager



Ilsa Jerome, Ph.D.,  
Research and  
Information Specialist



Rebecca Matthews,  
Clinical Trial Leader



Allison Wilens,  
Clinical Systems  
Analyst

**Founded in 1986**, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a **501(c)(3) non-profit** research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

### MAPS furthers its mission by:

- Developing psychedelics and marijuana into prescription medicines.
- Training therapists and working to establish a network of treatment centers.
- Supporting scientific research into spirituality, creativity, and neuroscience.
- Educating the public honestly about the risks and benefits of psychedelics and marijuana.

**MAPS envisions** a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

**MAPS relies** on the generosity of individual donors to achieve our mission. Now that research into the beneficial potential of psychedelics is again being conducted under federal guidelines, the challenge has become one of funding. No funding is currently available for this research from pharmaceutical companies or major foundations. That means that the future of psychedelic and marijuana research is in the hands of individual donors. Please consider making a donation today.

[maps.org/donate](https://maps.org/donate)